[go: up one dir, main page]

ES2150940T3 - Formulacion proteinica que comprende hormona del crecimiento. - Google Patents

Formulacion proteinica que comprende hormona del crecimiento.

Info

Publication number
ES2150940T3
ES2150940T3 ES93908252T ES93908252T ES2150940T3 ES 2150940 T3 ES2150940 T3 ES 2150940T3 ES 93908252 T ES93908252 T ES 93908252T ES 93908252 T ES93908252 T ES 93908252T ES 2150940 T3 ES2150940 T3 ES 2150940T3
Authority
ES
Spain
Prior art keywords
growth hormone
pct
formulation
citrate
buffer substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93908252T
Other languages
English (en)
Other versions
ES2150940T5 (es
Inventor
Staffan Castensson
Ebba Florin-Robertsson
Elvy Hokby
Sirkka Thome
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20385860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2150940(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Application granted granted Critical
Publication of ES2150940T3 publication Critical patent/ES2150940T3/es
Publication of ES2150940T5 publication Critical patent/ES2150940T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCION SE REFIERE A FORMULACIONES INYECTABLES DE HORMONA DE DESARROLLO O CUALQUIER ANALOGO FUNCIONAL DE LAS MISMAS, COMPRENDIENDO CITRATO COMO SUSTANCIA REGULADORA. LA FORMULACION PUEDE SER UNA SOLUCION ACUOSA DE HORMONA DE DESARROLLO Y CUALQUIER ANALOGO FUNCIONAL DE LA MISMA, Y CITRATO COMO SUSTANCIA REGULADORA, EN UNA CONCENTRACION DE 2-50 MM. LA FORMULACION DE LA HORMONA DEL DESARROLLO O CUALQUIER ANALOGO FUNCIONAL DE LA MISMA PUEDE COMPRENDER FACTORES DE DESARROLLO, AMINOACIDOS TALES COMO, POR EJEMPLO, GLICINA Y ALANINA Y/O MANNITOL O MANNITA, O BIEN OTROS ALCOHOLES DEL AZUCAR Y/O GLICEROL Y/O OTROS CARBOHIDRATOS Y, OPCIONALMENTE, UN PRESERVADOR TAL COMO ALCOHOL DE BENZILO. LA INVENCION TAMBIEN SE REFIERE A UN PROCESO PARA LA PREPARACION DE LA FORMULACION MEDIANTE LA MEZCLA DE LA HORMONA DEL DESARROLLO O DE CUALQUIER ANALOGO FUNCIONAL DE LA MISMA, CON CITRATO COMO SUSTANCIA REGULADORA, O BIEN AÑADIENDO LOS COMPONENTESA DE LA FORMULACION FINAL SOBRE LA FASE DE DEPURACION DEL GEL.
ES93908252T 1992-04-03 1993-04-01 Formulacion proteinica que comprende hormona del crecimiento. Expired - Lifetime ES2150940T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201073A SE9201073D0 (sv) 1992-04-03 1992-04-03 Protein formulation
SE9201073 1992-04-03

Publications (2)

Publication Number Publication Date
ES2150940T3 true ES2150940T3 (es) 2000-12-16
ES2150940T5 ES2150940T5 (es) 2008-04-16

Family

ID=20385860

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93908252T Expired - Lifetime ES2150940T5 (es) 1992-04-03 1993-04-01 Formulacion proteinica que comprende hormona del crecimiento.

Country Status (15)

Country Link
US (1) US5567677A (es)
EP (1) EP0587858B2 (es)
JP (1) JP3268557B2 (es)
AT (1) ATE196092T1 (es)
AU (1) AU666007B2 (es)
CA (1) CA2102693C (es)
DE (1) DE69329367T3 (es)
DK (1) DK0587858T3 (es)
ES (1) ES2150940T5 (es)
GR (1) GR3034925T3 (es)
NO (1) NO310804B1 (es)
NZ (1) NZ251498A (es)
PT (1) PT587858E (es)
SE (1) SE9201073D0 (es)
WO (1) WO1993019776A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AUPN801296A0 (en) 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
ZA9711733B (en) * 1996-12-31 1998-07-01 Monsanto Co Method for solubilization and naturation of somatotropins
ZA9711731B (en) * 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
JP2003504346A (ja) * 1999-07-12 2003-02-04 グランデイス・バイオテツク・ゲー・エム・ベー・ハー 成長ホルモン製剤
JP2004515467A (ja) 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
US7271150B2 (en) * 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7375073B2 (en) * 2002-02-27 2008-05-20 Wake Forest University Health Sciences Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
US20070065469A1 (en) * 2002-07-09 2007-03-22 Michael Betz Liquid formulations with high concentration of human growth hormone (high) comprising glycine
CA2491478A1 (en) * 2002-07-09 2004-01-15 Sandoz Ag Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
US20060252682A1 (en) * 2003-03-18 2006-11-09 Ares Trading S.A. Liquid growth hormone formulation and process of preparation thereof
JP4845741B2 (ja) 2003-12-23 2011-12-28 ファルマシア コーポレーション 安定な成長ホルモン液体製剤
ES2383994T3 (es) 2004-04-07 2012-06-28 Ares Trading S.A. Formulación líquida de hormona del crecimiento
CA2570324C (en) 2004-08-03 2014-07-22 Transtech Pharma, Inc. Rage fusion proteins and methods of use
AP2007003893A0 (en) * 2004-08-03 2007-02-28 Transtech Pharma Inc Rage fusion proteins and methods of use
WO2006022301A1 (ja) * 2004-08-24 2006-03-02 Daiichi Asubio Pharma Co., Ltd. 生理活性ペプチド液状製剤
KR101173717B1 (ko) * 2004-11-09 2012-08-13 아레스 트레이딩 에스.에이. Ｆｓｈ를 정제하는 방법
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
JP4944112B2 (ja) * 2005-08-26 2012-05-30 アレス トレーディング ソシエテ アノニム グリコシル化されたインターフェロンベータの調製方法
WO2007056105A2 (en) * 2005-11-02 2007-05-18 Transpharma Medical Ltd. Human growth hormone patch formulations
EP1960419B1 (en) * 2005-12-09 2016-03-16 Ares Trading S.A. Method for purifying fsh or a fsh mutant
EP1963786B1 (en) * 2005-12-23 2013-07-24 GCoder Systems AB Positioning pattern
WO2007094926A2 (en) * 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
EP2021474A2 (en) * 2006-05-05 2009-02-11 Transtech Pharma, Inc. Rage fusion proteins, formulations, and methods of use thereof
US20080199467A1 (en) * 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making
US8420779B2 (en) 2007-05-22 2013-04-16 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US20100256337A1 (en) * 2007-10-22 2010-10-07 Merck Serono Sa Method for purifying an fc-containing protein
CA2702448A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying fc-fusion proteins
BRPI1015019A2 (pt) 2009-04-20 2018-02-14 Pfizer controle de glicosilação de proteína e composições e métodos relacionada a ele.
EP2427215A1 (en) * 2009-05-07 2012-03-14 Novo Nordisk Health Care AG Stable pharmaceutical compositions of peptide derivatized using an oxime linker
CA2780554C (en) * 2009-11-17 2017-08-15 Ipsen Pharma S.A.S. Formulation for hgh and rhigf-1 combination
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
US10064951B2 (en) * 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
CA2925416A1 (en) * 2013-09-27 2015-04-02 Hanmi Pharm. Co., Ltd. Sustained type human growth hormone preparation
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
WO2016011281A1 (en) * 2014-07-17 2016-01-21 Teva Pharmaceutical Industries Ltd. FORMULATIONS OF AN ALBUMIN-hGH FUSION PROTEIN
KR20210024082A (ko) * 2018-06-25 2021-03-04 제이씨알 파마 가부시키가이샤 단백질 함유 수성 액제

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
DE3579911D1 (de) * 1984-12-24 1990-10-31 Sumitomo Pharma Stabiles grf-praeparat.
AU6073386A (en) * 1985-07-30 1987-02-05 International Minerals & Chemical Corporation Stabilization of growth promoting hormones
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
DE3782737T3 (de) * 1987-08-21 1999-05-20 Imcera Group Inc., Northbrook, Ill. Stabilisierung von Wachstumshormonen.
US4837202A (en) † 1987-09-14 1989-06-06 Pitman-Moore, Inc. Method for stimulating the immune system
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH01308235A (ja) * 1988-06-03 1989-12-12 Yamanouchi Pharmaceut Co Ltd ヒト成長ホルモン経鼻剤
US5008244A (en) * 1989-05-15 1991-04-16 Pitman-Moore, Inc. Method for increasing fertility in animals
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
IN172427B (es) * 1989-11-14 1993-07-24 Fidia Spa
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU1757092A (en) * 1991-03-28 1992-11-02 Genentech Inc. Stable growth hormone metal ion formulations
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
AU679913B2 (en) * 1992-04-30 1997-07-17 Millennium Pharmaceuticals, Inc. Stable polypeptide composition
CA2489978A1 (en) * 1992-07-31 1994-02-17 Genentech, Inc. Human growth hormone aqueous formulation

Also Published As

Publication number Publication date
PT587858E (pt) 2001-02-28
EP0587858A1 (en) 1994-03-23
NO310804B1 (no) 2001-09-03
JP3268557B2 (ja) 2002-03-25
NZ251498A (en) 1995-07-26
ATE196092T1 (de) 2000-09-15
EP0587858B1 (en) 2000-09-06
ES2150940T5 (es) 2008-04-16
NO934355L (no) 1993-12-01
NO934355D0 (no) 1993-11-30
DE69329367T3 (de) 2008-06-19
DK0587858T3 (da) 2000-12-18
WO1993019776A1 (en) 1993-10-14
GR3034925T3 (en) 2001-02-28
DE69329367T2 (de) 2001-06-21
AU666007B2 (en) 1996-01-25
CA2102693A1 (en) 1993-10-04
CA2102693C (en) 2008-06-17
AU3913593A (en) 1993-11-08
US5567677A (en) 1996-10-22
DE69329367D1 (de) 2000-10-12
EP0587858B2 (en) 2007-11-14
JPH06508156A (ja) 1994-09-14
SE9201073D0 (sv) 1992-04-03

Similar Documents

Publication Publication Date Title
ES2150940T3 (es) Formulacion proteinica que comprende hormona del crecimiento.
ATE255450T1 (de) Matrix für iontophorese
CA2275890A1 (en) Stable liquid interferon formulations
DK0910399T3 (da) Stabilt farmaceutisk BDNF-præparat
DE59504750D1 (de) Verfahren zur gewinnung von hochreinem von willebrand-faktor
DK1017413T3 (da) Flydende formulering af interferon-beta
DK1044015T3 (da) Formuleringer med amylinagonistpeptider og insulin
ES2187820T3 (es) Formulaciones farmaceuticas de factor de liberacion de la corticotrop ina que tiene una estabilidad en su forma liquida.
DE69805983D1 (de) Hustenhemmende, theobromine enthaltende zusammensetzungen
ES2103369T3 (es) Derivados de lanolina como sustancias que aceleran la penetracion y su aplicacion en sustancias farmaceuticas u otras formulaciones que contienen sustancias biologicamente activas.
KR860006982A (ko) 안정한 감마 인터페론 제형의 제조방법
Donohue Jr et al. Glucose-6-phosphate dehydrogenase Partial characterization of the rat liver and uterine enzymes
Leaver Studies on certain peptide fractions isolated from human dentine
ATE187077T1 (de) Wässrige zubereitung mit verzögerter wirkstofffreigabe
Lafeber Comparison of PTH and hypocalcin in mammalian and teleost bioassays
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio
El‐Mallah et al. Free Aminoacids and Serotonin Contents in Cows Pineal Extract
KR920700666A (ko) 소형 펩티드의 안정화 액상제제
TH8733A (th) ตัวปลุกฤทธิ์โปรตีนไคเนสเป็นตัวกระตุ้นการผลิตเมลานิน
RU2071681C1 (ru) Состав для жирования кож

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 587858

Country of ref document: ES